Neuropeptide Y (NPY) attenuates vagal effects on cardiac cycle length, presumably by inhibiting the release of acetylcholine from vagal nerve endings. We sought to determine if NPY inhibited the vagal effects on atrioventricular (AV) interval and atrial contraction in a manner similar to its inhibition of the vagal effects on cycle length. In 19 anesthetized dogs we measured the vagal effects on cycle length, AV Interval, and atrial contraction before and after 3-minute trains of sympathetic stimulation or before and after exogenous NPY (20 /ig/kg i.v.). Three minutes after 10-Hz sympathetic stimulation, the vagal effects on cycle length and AV interval were attenuated by 52±9% and 63±8%, respectively. Phentolamine significantly augmented this attenuation, but propranolol had no appreciable effect. In the control group of animals or in the group that received phentolamine, the vagal effects on atrial contraction measured before and after sympathetic stimulation were not significantly different. In these two groups, however, the basal atrial contraction was reduced substantially after the cessation of sympathetic stimulation. Propranolol prevented this reduction in atrial contraction. After propranolol, the vagal effects on atrial contraction 3 minutes after sympathetic stimulation were attenuated by 31 ±6%. Exogenous NPY had no direct effect on cycle length, AV interval, or atrial contraction, but exogenous NPY did persistently inhibit the vagal effects on each of these cardiac processes. Three minutes after NPY was given, the vagal effects on cycle length, AV interval, and atrial contraction were inhibited by 62±7%, 69±5%, and 68±5%, respectively. We conclude that NPY attenuates the vagal effects on the atrial myocardium and on the sinus and AV nodes. In the absence of ^-blockade, the inhibitory effect of neurally released NPY on the vagally induced decreases in atrial contraction may be masked by the reduction in the atrial contraction that occurs after sympathetic stimulation. (Circulation Research 1989;65:1536-1546 I t has long been recognized that the autonomic nervous system modulates cardiac function by releasing the neurotransmitters norepinephrine and acetylcholine. 1 More recent data indicate that most cardiac autonomic neurons also contain one or more neuropeptides that are released concomitantly with these "classical" neurotransmitters. 2 -8 The neuropeptides released from cardiac autonomic neurons may act as neurotransmitters or neuromodulators and, thereby, participate in the autonomic neural control of the heart.
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Neuropeptide Y (NPY) attenuates vagal effects on cardiac cycle length, presumably by inhibiting the release of acetylcholine from vagal nerve endings. We sought to determine if NPY inhibited the vagal effects on atrioventricular (AV) interval and atrial contraction in a manner similar to its inhibition of the vagal effects on cycle length. In 19 anesthetized dogs we measured the vagal effects on cycle length, AV Interval, and atrial contraction before and after 3-minute trains of sympathetic stimulation or before and after exogenous NPY (20 /ig/kg i.v.). Three minutes after 10-Hz sympathetic stimulation, the vagal effects on cycle length and AV interval were attenuated by 52±9% and 63±8%, respectively. Phentolamine significantly augmented this attenuation, but propranolol had no appreciable effect. In the control group of animals or in the group that received phentolamine, the vagal effects on atrial contraction measured before and after sympathetic stimulation were not significantly different. In these two groups, however, the basal atrial contraction was reduced substantially after the cessation of sympathetic stimulation. Propranolol prevented this reduction in atrial contraction. After propranolol, the vagal effects on atrial contraction 3 minutes after sympathetic stimulation were attenuated by 31 ±6%. Exogenous NPY had no direct effect on cycle length, AV interval, or atrial contraction, but exogenous NPY did persistently inhibit the vagal effects on each of these cardiac processes. Three minutes after NPY was given, the vagal effects on cycle length, AV interval, and atrial contraction were inhibited by 62±7%, 69±5%, and 68±5%, respectively. We conclude that NPY attenuates the vagal effects on the atrial myocardium and on the sinus and AV nodes. In the absence of ^-blockade, the inhibitory effect of neurally released NPY on the vagally induced decreases in atrial contraction may be masked by the reduction in the atrial contraction that occurs after sympathetic stimulation. (Circulation Research 1989; 65:1536 -1546 I t has long been recognized that the autonomic nervous system modulates cardiac function by releasing the neurotransmitters norepinephrine and acetylcholine. 1 More recent data indicate that most cardiac autonomic neurons also contain one or more neuropeptides that are released concomitantly with these "classical" neurotransmitters. 2 -8 The neuropeptides released from cardiac autonomic neurons may act as neurotransmitters or neuromodulators and, thereby, participate in the autonomic neural control of the heart.
Neuropeptide Y is colocalized with norepinephrine in sympathetic nerve terminals throughout the heart, 2 -3 ' 5 and both neuropeptide Y and norepinephrine are released on sympathetic activation. 7 -910 Evidence indicates that, in the heart, neuropeptide Y attenuates the release of acetylcholine and norepinephrine from parasympathetic and sympathetic nerve terminals, respectively. 11 " 14 In isolated guinea pig atria, exogenous neuropeptide Y had no appreciable effect on the chronotropic and inotropic responses to exogenous norepinephrine or acetylcholine, but the neuropeptide Y did attenuate the cardiac responses evoked by field stimulation. 11 Similarly, in the anesthetized dog, neurally released or exogenous neuropeptide Y had no significant effect on the negative chronotropic response to the cholinergic agonist bethanechol, but neuropeptide Y did substantially attenuate the chronotropic response to vagal stimulation. 14 Thus , neuropeptide Y appears to act presynapticalry on cardiac autonomic nerve terminals to modulate the release of acetylcholine and norepinephrine.
The extent of peripheral sympathetic-parasympathetic interaction varies substantially, depending on the cardiac response under consideration. 15 For example, interactions involving the chronotropic responses of the sinus node are pronounced, whereas those involving the dromotropic responses of the atrioventricular (AV) node are much less prominent. 15 Although neuropeptide Y attenuates vagally induced cardiac cycle length responses, 14 ' 16 ' 17 it is unknown whether neuropeptide Y persistently inhibits the vagal effects on other cardiac processes. Therefore, we sought to determine if neurally released or exogenous neuropeptide Y attenuated the vagal effects on AV conduction and atrial contractility in a manner similar to its attenuation of the vagal effects on cardiac cycle length.
Materials and Methods
Nineteen mongrel dogs (10-24 kg) were premedicated with morphine sulfate (2 mg/kg i.m.) and anesthetized with a-chloralose (100 mg/kg i.v.). A tracheal cannula was inserted through a midline cervical incision, and intermittent positive pressure ventilation was begun. Saline-filled cannulae were placed in the left femoral artery and vein for arterial pressure measurement and drug administration, respectively. The right and left cervical vagi were isolated and ligated to interrupt parasympathetic nerve activity. Bipolar hook electrodes were inserted into the cardiac end of each vagus nerve, and the electrode wires were connected to stimulators (model S9, Grass Instruments, Quincy, Massachusetts).
The chest was opened transversely at the fourth intercostal space. The right and left stellate ganglia were isolated and crushed by ligation to eliminate cardiac sympathetic nerve activity. The right and left ansae subclaviae were placed over bipolar stimulating electrodes (Harvard Apparatus, South Natick, Massachusetts), and the electrode wires were connected in parallel to a Grass stimulator (model S9).
A plaque containing two bipolar electrode pairs was sutured to the right atrium along the sulcus terminalis midway between the superior and inferior venae cavae. We recorded an atrial electrogram from one bipolar electrode, and we used the other bipolar electrode for atrial pacing. We also recorded a ventricular electrogram from a bipolar electrode sutured to the right ventricle.
Through a 1-cm incision in the apex of the right atrial appendage, we inserted a small deflated balloon attached to a hollow rigid tube. We used a ligature to anchor the balloon within the atrial appendage. We then filled the balloon and tube with 1-2 ml saline. To monitor pressure in the balloon, we connected the rigid tube to a Statham transducer (model P23BB, Gould, Cleveland, Ohio). We used the difference between the maximum and minimum pressures in the balloon during each cardiac cycle as an index of the strength of atrial contraction. To assess whether a change in balloon pressure was a reliable index of atrial contractile force, we compared changes in balloon pressure with changes in force recorded with a Walton-Brodie strain gauge arch in four animals. The strain gauge arch was sutured to the right atrial free wall. During all experimental protocols, the changes in balloon pressure paralleled the changes in force measured with the strain gauge arch.
The right atrial electrogram, right ventricular electrogram, arterial blood pressure, atrial contraction (balloon and strain gauge arch), cycle length, and AV interval were recorded on a Gould electrostatic recorder (model RS1000) and on magnetic tape. All signals were displayed on a Gould monitor (model V1000).
The cardiac cycle length (AA interval) was defined as the interval between two atrial depolarizations, and the AV interval was denned as the interval between atrial and ventricular depolarization. The AA and AV intervals were determined from the electrograms by an analog computer (model 580, Electronic Associates, West Long Beach, New Jersey) that measured the intervals accurately to within 1 msec.
Vagal Stimulation Protocol
We examined the effects of vagal stimulation on cardiac cycle length, AV conduction, and atrial contraction ( Figure 1 ). During atrial pacing, we stimulated the left vagus nerve supramaximally (3-4 V, 1-msec pulse width) for 10 seconds. The frequency of left vagal stimulation was 80% of the minimum stimulation frequency that produced loss of 1 : 1 AV conduction. The frequencies of left vagal stimulation ranged from 1.5 to 3.2 Hz in individual animals. In response to vagal stimulation, the AV interval increased from a control of 117.3±5.0 to 161.2±6.1 msec (n-19, mean±SEM). Thus, the AV conduction time was prolonged substantially, but 1 = 1 AV conduction prevailed. We also measured the effect of left vagal stimulation on the atrial contraction. Note that we measured the vagal effects on AV interval and atrial contraction only during atrial pacing. The atrial pacing eliminated any confounding influence of vagally induced changes in cardiac cycle length on the AV conduction or atrial contraction responses. The right atrium was paced at a cycle length 20-85 msec shorter than the spontaneous prepacing cycle length. The spontaneous cycle length ranged from 360 to 605 msec in individual animals.
Twenty seconds after the cessation of the left vagal stimulation, we interrupted the atrial pacing and allowed the heart to beat spontaneously ( Figure  1 ). In the absence of atrial pacing, we measured the cycle length response to a 10-second train of right vagal stimulation. We adjusted the frequency of right vagal stimulation to increase cardiac cycle length by about 100% (e.g., from 500 to 1,000 msec). The frequencies of right vagal stimulation ranged from 2.2 to 4.3 Hz in individual animals. The vagal stimulation increased the cardiac cycle length from a control of 493.2+18.7 to 997.9±37.2 msec (n = 19, mean±SEM). Although the frequencies of right and left vagal stimulation varied in individual animals, the other stimulus characteristics were maintained at supramaximal levels (i.e., 3-4 V, 1-msec pulse width). Note that the individual nerves (i.e., right or left vagus) were stimulated for only 10 seconds every 2 minutes. This method of vagal stimulation produced very stable cardiac responses in the present and previous studies. 17 
Sympathetic Stimulation Protocol
The ansae subclaviae were stimulated supramaximally (7-10 V, 1-msec pulse width) at frequencies of 5 and 10 Hz. The sympathetic stimulations were applied for a train duration of 3 minutes.
Experimental Protocols
Series 1: Neuralfy released neuropeptide Y. Animals were assigned randomly to a control (n=4), propranolol (n=5), or phentolamine (n=5) group. Each experiment, regardless of group, was subdivided into two observation periods. During the first observation period, we investigated the effect of 3-minute trains of sympathetic stimulation (5 and 10 Hz) on vagally induced cardiac chronotropic, inotropic, and dromotropic responses. At the end of observation period 1, we administered saline, propranolol, or phentolamine to animals in the control, propranolol, and phentolamine groups, respectively. During observation period 2, we repeated the 3-minute trains of sympathetic stimulation at frequencies of 5 and 10 Hz and determined their effect on the vagally induced cardiac responses. In the control group, comparison of the responses obtained during periods 1 and 2 provided information on the changes in cardiac responses over time.
In the propranolol and phentolamine groups, period 1 served as an internal control for the effects of propranolol and phentolamine, respectively.
Series 2: Exogenous neuropeptide Y.
We used the protocol shown in Figure 1 to obtain control responses to vagal stimulation. We then administered neuropeptide Y (20 u.g/kg i.v.) in the presence (n=2) or absence (n=3) of atrial pacing. For the next 6 minutes, we monitored the direct effects of the exogenous neuropeptide Y on the cardiac cycle length, AV interval, atrial contraction, and arterial pressure. After this 6-minute period, we again applied the vagal stimulation protocol shown in Figure 1 . We used a 6-minute observation period, because this equaled the time interval that we had used for sympathetic stimulation in our series 1 experiments (i.e., in the series 1 experiments, we appliedJL 3 -minute train of sympathetic stimulation and allowed a 3-minute recovery period before resuming the vagal stimulation protocol). We Drugs. We administered phentolamine (1 mg/kg i.v., followed by 2 mg/kg/hr i.v.) to block aadrenergic receptors. The absence of an increase in arterial pressure to a bolus of phenylephrine (2-8 /i-g/kg i.v.) constituted evidence for effective aadrenergic receptor antagonism. The phenylephrine increased arterial pressure by 36±6 mm Hg (n=5) under control conditions. To block /3-adrenergic receptors, we administered propranolol (1 mg/kg i.v. followed by 1 mg/kg/hr i.v.). We considered the blockade of )9-adrenergic receptors to be adequate if the cardiac cycle length did not decrease in response to supramaximal sympathetic stimulation applied at a frequency of 10 Hz.
Data Analysis
We used a paired t test to compare two groups of data. To compare three or more groups of data, we used analysis of variance. If the F statistic was significant, we made individual comparisons between groups with the Bonferroni modified t test. 18 We considered a significance level of p<5% to be statistically significant. We determined the areas above certain curves by integration. Data are presented as mean±SEM.
Results
Representative Experiment: Series 1 Figure 2 shows a representative example of the cardiac responses to our stimulation protocol. During the control period (Figure 2A ), the right atrium was initially paced at a cycle length of 480 msec. During atrial pacing, left vagal stimulation increased the AV interval to 160 msec from a control of 105 msec (top tracing) and decreased the atrial contraction to 20 mm from a control of 36 mm (bottom tracing). About 15 seconds after the cessation of left vagal stimulation, the atrial pacing was interrupted. While the heart was beating spontaneously, we stimulated the right vagus nerve. Right vagal stimulation increased the cardiac cycle length to 1,200 msec from a control of 560 msec (middle tracing). After we had completed the control vagal stimulations (Figure 2A ), we applied a 3 -minute train of stimulation, at a frequency of 10 Hz, to the ansae subclaviae. Figure 2A shows the cardiac responses to the first 45 seconds of sympathetic stimulation. During the sympathetic stimulation, the cardiac cycle length and AV interval decreased, and the atrial contraction increased.
Three minutes after the termination of sympathetic stimulation ( Figure 2B ), we repeated the vagal stimulation protocol that we had applied before sympathetic stimulation. Right vagal stimulation now increased the cardiac cycle length to only 640 msec from a control of 530 msec, and left vagal stimulation (during atrial pacing) increased the AV interval to only 115 msec from a control of 100 msec. Although we used the identical vagal stimulation protocol before and after sympathetic stimulation, the vagally induced AV interval and cycle length responses were inhibited by 73% and 82%, respectively, 3 minutes after the cessation of sympathetic stimulation.
We continued to stimulate the vagi every other minute until the vagally induced cardiac responses had returned to control. Seventeen minutes after sympathetic stimulation ( Figure 2C ), the vagally induced AV interval and cycle length responses were now inhibited by only 34% and 53%, respectively. At 38 minutes after sympathetic stimulation, the vagally induced AV interval and cycle length responses had returned to control (data not shown). Figure 3 shows representative examples of the recovery of vagally induced AV interval and cycle length responses after the termination of 3-minute trains of sympathetic stimulation. In response to such trains at frequencies of 5 or 10 Hz (Figure 3 ), the inhibition of the vagal effects on AV interval was similar in magnitude and duration to the inhibition of the vagal effects on cardiac cycle length. Note, however, that increasing the frequency of sympathetic stimulation from 5 to 10 Hz augmented substantially the magnitude and duration of the inhibitory effects on these responses. We characterized the sympathetically mediated inhibition of the vagal effects on AV interval and cycle length by determining the initial and summated inhibitions. We defined the initial inhibition as the attenuation of the first vagally induced AV interval or cycle length response after the cessation of sympathetic stimulation (i.e., at 2 or 3 minutes in Figure 3 ). We calculated the initial inhibition as 100(R C -R e )/R c , where R<. is the control vagally induced response and R,. is the first "experimental" response that we obtained after the termination of sympathetic stimulation. In Figure 3 , the initial inhibitions of the AV interval and cycle length responses after the 5-Hz train of sympathetic stimulation were 40% and 50%, respectively. We defined the summated inhibition as the area between the appropriate response curve and the dashed horizontal line (Figure 3 ), which represents 100% of the control response. We determined this area by integration.
The inhibition of the vagal effects on the atrial contraction was difficult to assess, because the basal atrial contraction (i.e., the atrial contraction in the absence of neural stimulation) was markedly reduced for some time after sympathetic stimulation. Figure 2A shows that before sympathetic stimulation the basal atrial contraction was 36 mm and that the sympathetic stimulation increased the atrial contraction to 78 mm. Three minutes after sympathetic stimulation ( Figure 2B ), the basal atrial contraction had decreased to 16 mm, a 56% reduction from control. In contrast, the cycle length and AV interval had returned to values near their basal levels by 3 minutes after sympathetic stimulation. The basal atrial contraction only gradually returned to control, and at 17 minutes after sympathetic stimulation ( Figure 2C) , it had increased to 27 mm (i.e., about halfway back to the basal level that had prevailed before sympathetic stimulation).
Although the basal atrial contraction was substantially reduced 3 minutes after sympathetic stimulation, vagal stimulation still evoked pronounced additional decreases in the atrial contraction. For example, in Figure 2B , left vagal stimulation (during atrial pacing) decreased the atrial contraction to 8 mm from a control of 16 mm, a 50% reduction. In comparison, before sympathetic stimulation ( Figure  2A) , left vagal stimulation reduced the atrial contraction to 20 mm from a control of 36 mm, a 44% reduction. Thus, vagal stimulation produced a slightly greater fractional reduction in the atrial contraction amplitude after sympathetic stimulation than it did before sympathetic stimulation.
We did not calculate the initial and summated inhibitions of vagally induced atrial contractility responses, because the basal atrial contraction after sympathetic stimulation was substantially different from the basal atrial contraction before sympathetic stimulation (e.g., Figure 2 ). We have summarized separately the atrial contraction data below (Figures 6-8 ).
Composite Data: Series 1
We examined the effect of 3-minute trains of sympathetic stimulation applied at frequencies of 5 and 10 Hz on vagally induced cardiac responses in three experimental groups: a control group, a propranolol group, and a phentolamine group. Figures  4 and 5 summarize the initial and summated inhibition data. In period 1, the effect of the 5 and 10 Hz trains of sympathetic stimulation on vagally induced cardiac responses served as an internal control for each of the experimental groups. After period 1 was completed, saline, propranolol, or phentolamine was given to animals in the corresponding groups. We then repeated the 5 and 10 Hz trains of sympathetic stimulation during period 2.
In the control and propranolol groups, the initial and summated inhibitions obtained during period 1 were not significantly different from those obtained during period 2 for both the AV interval ( Figure 4 ) and cycle length ( Figure 5 ) responses. In contrast, after phentolamine, the initial and summated inhibitions of vagally induced AV interval and cardiac cycle length responses were significantly augmented (Figures 4 and 5 , respectively; /?<0.01). Also note that during periods 1 and 2 in all three groups of animals, raising the frequency of sympathetic stimulation significantly increased the initial and summated inhibitions of the vagally induced AV interval and cycle length responses (p<0.05). Figure 6 summarizes the atrial contraction responses to sympathetic stimulation in the three experimental groups. During period 1 in all groups, sympathetic stimulation at 5 and 10 Hz increased significantly the atrial contraction (p<0.001). Furthermore, during period 1 in all groups, the basal atrial contraction measured 3 minutes after the cessation of sympathetic stimulation was substantially smaller (/?<0.02) than the basal atrial contraction measured before sympathetic stimulation. We observed similar changes in the basal atrial contraction during period 1 2 in the control and phentolamine groups. After propranolol (i.e., period 2 in the propranolol group), as expected, sympathetic stimulation at 5 or 10 Hz did not significantly increase the atrial contraction ( Figure 6 ). Moreover, in the presence of propranolol, the basal atrial contraction measured 3 minutes after sympathetic stimulation was not significantly different from that measured before sympathetic stimulation.
In an effort to quantitate the effects of vagal stimulation on atrial contractility, we calculated the vagally induced decrease in the atrial contraction as a percent of the basal atrial contraction measured immediately (i.e., 5 seconds) before a given vagal stimulation (Figure 7 ). For example, in Figure 2 , vagal stimulation decreased the atrial contraction by 44% before sympathetic stimulation and by 50% after sympathetic stimulation. This calculation allowed us to normalize the data from the three experimental groups. The normalization was neces- Figure 4 . During period 1 in all groups, sympathetic stimulation increased significantly the atrial contraction, and 3 minutes after the termination of sympathetic stimulation, the atrial contraction was significantly less than control. During period 2 in the propranolol group only, there was no significant change in the atrial contraction during or after sympathetic stimulation. period 2 in the control and phentolamine groups ( Figure 6 ). During period 1 in all groups (Figure 7) , the percent vagally induced reductions in the atrial contractions measured before and 3 minutes after sympathetic stimulation were not significantly different. Thus, it appeared that sympathetic stimulation did not inhibit the vagal effects on atrial contraction during period 1. Similarly, during period 2 in the control and phentolamine groups, sympathetic stimulation did not significantly affect the subsequent vagally induced decreases in the atrial contraction. In contrast, after propranolol, sympathetic stimulation at 5 and 10 Hz significantly attenuated the subsequent vagally induced decreases in the atrial contraction.
The data in Figure 6 suggest that neurally released norepinephrine significantly increases the atrial contraction during sympathetic stimulation and that it also reduces the basal atrial contraction after the termination of sympathetic stimulation. To test this hypothesis we measured the atrial contraction responses to exogenous norepinephrine. We also examined vagally induced atrial contraction responses before and after exogenous norepinephrine.
We infused norepinephrine (1-4 ^.g/kg/min i.v.) to increase the atrial contraction for 3 minutes, in an attempt to simulate the changes in atrial contraction evoked by a 3-minute train of sympathetic stimulation (10 Hz). The exogenous norepinephrine increased (/><0.001) the atrial contraction, as expected (Figure 8 ). Three minutes after the cessation of the norepinephrine infusion, the basal atrial contraction decreased (p<0.05) below that measured before the norepinephrine infusion (Figure 8 , open bars). Although the basal atrial contraction was reduced initially, it gradually returned to con- trol with a time course similar to that observed after sympathetic stimulation (e.g., Figure 2 ). After the norepinephrine infusion, the mean time for the basal atrial contraction to return to 90% of control was 16.6±1.7 minutes (n=5). In comparison, after 3-minute trains of 10 Hz sympathetic stimulation, the mean time for the atrial contraction to return to 90% of control was 25.2±3.4 minutes (n=5). In addition, vagal stimulation evoked similar fractional reductions in the atrial contraction before and after the norepinephrine infusion (Figure 8, filled bars) . The vagal stimulation reduced the atrial contraction by 56.6% before the norepinephrine infusion and by 55.8% 3 minutes after the norepinephrine infusion.
Series 2: Exogenous Neuropeptide Y
Exogenous neuropeptide Y increased slightly the cardiac cycle length and AV interval and decreased slightly the atrial contraction (Table 1) , but these effects were not significant. In contrast, neuropep- tide Y did increase the mean arterial pressure significantly (/?<0.01) at 3 and 6 minutes ( Table 1) . Twenty minutes after neuropeptide Y was given, the mean arterial pressure was slightly, but not significantly, elevated. The exogenous neuropeptide Y persistently attenuated the vagal effects on cardiac cycle length, AV interval, and atrial contraction ( Figure 9 and Table  2 ). Figure 9 shows the recovery of vagally induced cardiac responses after the administration of exogenous neuropeptide Y in a representative animal. The initial inhibitions of the vagal effects on cardiac cycle length, AV interval, and atrial contraction were 80%, 88%, and 63%, respectively. The vagally induced cardiac responses returned slowly to control over 2 hours. Table 2 summarizes the effects of exogenous neuropeptide Y on the initial and summated inhibitions of the vagally induced cardiac responses in five animals. The initial or summated inhibitions of the vagal effects on cardiac cycle length, AV interval, and atrial contraction were not signifi- 
Discussion

Effects of Neuropeptide Y at the Sinus and AV Nodes
Our data show that vagal effects at the sinus and AV nodes are attenuated after the cessation of brief trains of sympathetic stimulation in autonomically decentralized anesthetized dogs. The attenuation is presumably due to the release of neuropeptide Y from sympathetic nerve terminals. 7, 9, 14, 16, 17 xh. e persistent inhibition of vagal effects at the sinus and AV nodes that occurs after the termination of sympathetic stimulation 1) depends on the frequency of sympathetic stimulation, 2) is enhanced significantly by phentolamine, and 3) is not affected appreciably by propranolol. Exogenous neuropeptide Y did not directly affect the cardiac cycle length or AV interval, but exogenous neuropeptide Y did persistently attenuate vagally induced chronotropic and dromotropic responses.
Our observations (Figures 2-4 ) that the vagal effects on AV interval are substantially reduced after the cessation of short trains of sympathetic stimulation extend the findings in previous studies that sympathetic stimulation attenuates vagally induced chronotropic responses. 14 -16 -17 Immunohistochemical and radioimmunoassay data indicate that neuropeptide Y is colocalized with norepinephrine in most cardiac sympathetic neurons. 2 -3 -5 - 8 The sinus and AV nodes receive an especially rich innervation by sympathetic neurons that contain neuropeptide Y. 58 Our data suggest that neuropeptide Y, released from sympathetic nerve terminals in the sinus and AV nodal regions, inhibits the effects of vagal stimulation on chronotropic and dromotropic responses.
The proximity of sympathetic and vagal nerve endings in the heart provides the anatomic substrate for neurotransmitters or neuromodulators released from one fiber type to interact with terminals of the other fiber type. 15 -19 In "conventional" cardiac sympathetic-parasympathetic interactions involving norepinephrine and acetylcholine, 15 ' 19 it has been shown that parasympathetic effects predominate over sympathetic effects in the control of cycle length. 15 ' 19 -21 In contrast, studies of AV conduction have shown that the interactions are either undetectable 20 or that sympathetic effects predominate over parasympathetic effects. 21 Prejunctional and postjunctional actions of norepinephrine and acetylcholine mainly underlie these peripheral sympathetic-parasympathetic interactions. 15 ' 19 Our present data show that the inhibition of the vagal effects on cycle length mediated by a train of sympathetic stimuli is similar in magnitude and duration to the inhibition of the vagal effects on AV interval (Figures 2-5 ). This suggests that neuropeptide Y, released from sympathetic nerve endings, acts similarly on vagal nerve terminals in the sinus and AV nodes to diminish the release of acetylcholine. Thus, in contrast to previously described adrenergic-cholinergic interactions, 15 -19 -21 the inhibition of vagal effects that occurs after the cessation of sympathetic stimulation is similar on cardiac chronotropic and dromotropic responses. Because the release of neuropeptide Y from cardiac sympathetic nerve terminals has only recently been established, it is unclear to what extent neuropeptide Y modulates cardiac adrenergic-cholinergic interactions. We can hypothesize that some of the differences in adrenergic-cholinergic interactions in various cardiac structures may be explained by the prejunctional and postjunctional actions of neuropeptide Y released concomitantly with norepinephrine during sympathetic stimulation.
The activation of a-and /3-adrenergic receptors located on sympathetic nerve terminals modulates the release of norepinephrine. 22 ' 23 The release of neuropeptide Y from sympathetic nerve terminals is also affected by adrenergic receptor mechanisms. 7.9.10.24.25 i n the anesthetized pig, Rudehill et al 7 demonstrated that the stimulation-evoked release of neuropeptide Y from cardiac sympathetic neurons increased threefold in the presence of aadrenergic receptor blockade. Similarly, Pernow et al 25 showed that, in humans, phentolamine enhanced by up to fivefold the exercise-induced increase in the venous plasma content of neuropeptide Y, whereas clonidine reduced by 35% the increase in plasma neuropeptide Y. Our data suggest that the effects of a-adrenergic receptor blockade on the stimulation-evoked release of neuropeptide Y are functionally significant. Indeed, phentolamine augmented significantly the magnitude and duration of the sympathetically mediated inhibition of the vagal effects on AV interval and cardiac cycle length (Figures 4 and 5) . These data suggest that, for a given level of sympathetic activity, a-adrenergic receptor blockade enhanced the release of neuropeptide Y and, thereby, augmented the inhibition of the vagal effects at the sinus and AV nodes. In contrast, in the control and propranolol groups, the inhibitions obtained during period 2 were not significantly different from those obtained during period 1 (Figures 4 and 5) . Thus, neither the passage of time nor /3-adrenergic blockade affected the responses appreciably.
Effects of Nenropeptide Y on Atrial Contraction
The well-known positive inotropic effect of sympathetic stimulation is due mainly to the activation of /3-adrenergic receptors on cardiac myocytes by norepinephrine. 1 -26 Activation of postjunctional aadrenergic receptors may also contribute to this response. 2 * We found that sympathetic stimulation increased the atrial contraction, as expected ( Figures 2 and 6 ). However, on the termination of sympathetic stimulation, the atrial contraction decreased substantially below the atrial contraction measured before the sympathetic stimulation. The basal atrial contraction gradually returned to its presympathetic stimulation level over 20 minutes (e.g., Figure 2 ). The percent reductions in atrial contraction induced by vagal stimulation were similar before and after sympathetic stimulation during period 1 in all groups and during period 2 in the control and phentolamine groups (Figure 7) . The validity of these observations as an index of the efficacy of vagal stimulation, however, was difficult to assess because of the substantial reduction in the basal atrial contraction for a considerable time after sympathetic stimulation (Figures 2 and 6) .
The data we obtained after propranolol, however, show that the vagal effects on atrial contraction were attenuated after sympathetic stimulation in a manner similar to that observed at the sinus and AV nodes. Because 0-adrenergic receptor blockade eliminated the pronounced sympathetically induced changes in the atrial contraction ( Figure 6 ), we could compare the vagal effects on the atrial contraction before and after the sympathetic stimulation without the confounding effect of a change in the basal amplitude of contraction. In the animals treated with propranolol, the effects of vagal stimulation on the atrial contraction were significantly attenuated after the cessation of sympathetic stimulation ( Figure 7) . These data suggest that neuropeptide Y, released during sympathetic stimulation, inhibited the vagal effects on the atrial contraction. Furthermore, our exogenous neuropeptide Y data show clearly that neuropeptide Y persistently attenuates the vagal effects on atrial contraction ( Figure  9 ). Indeed, exogenous neuropeptide Y evoked a similar attenuation of the vagal effects on atrial contractility, cycle length, and AV interval ( Figure  9 and Table 2 ).
The mechanisms responsible for the sustained decrease in atrial contraction that occurs after sympathetic stimulation in the absence of /3-blockade are unclear. We initially hypothesized that neuralry released neuropeptide Y decreased the atria! contraction. Indeed, in isolated atrial and ventricular muscle strips, exogenous neuropeptide Y elicits negative inotropic effects. 27 In our study, however, the atrial contraction was not significantly altered after sympathetic stimulation if propranolol had been given ( Figure 6 ). Propranolol does not interfere with neuropeptide Y release. 10 Therefore, neu-rally released neuropeptide Y per se did not depress the atrial contraction in our experiments. Moreover, exogenous neuropeptide Y administered at a dose that substantially inhibited the vagally induced cardiac responses (Figure 9 ) had no significant direct effect on the atrial contraction (Table 1) .
Although neuropeptide Y does not appear to contribute to the decrease in atrial contraction after sympathetic stimulation, norepinephrine does. The atrial contraction response to an infusion of norepinephrine mimicked that evoked by sympathetic stimulation (Figures 6 and 8) . Thus, the reduction in atrial contraction after the termination of sympathetic stimulation or norepinephrine infusion appears to depend directly or indirectly on the activation of /3-receptors.
The reduction in the atrial contraction amplitude after sympathetic stimulation may have affected the atrial response to vagal stimulation. Although a given vagal stimulation evoked a similar percent effect on a normal and on a "weakened" atrial contraction (Figure 7) , the vagal stimulation induced a greater absolute change in the atrial contraction in the normal than in the weakened atrium. For example in Figure 2 , before sympathetic stimulation, the vagal stimulation reduced the atrial contraction by 16 mm, whereas 3 minutes after sympathetic stimulation the identical vagal stimulation reduced the atrial contraction by only 8 mm. Because the basal atrial contractions were markedly different, however, the percent vagally induced reductions were similar. Future investigations are needed to determine whether vagal effectiveness is modulated by the weakened atrial contraction and to determine the mechanisms responsible for the reduction in atrial contraction observed after the cessation of sympathetic stimulation.
Our data show that neurally released and exogenous neuropeptide Y attenuate the parasympathetic effects on the atrial myocardium and at the sinus and AV nodes. In the absence of /3blockade, the effect of neurally released neuropeptide Y on vagally induced decreases in atrial contraction may be masked by the reduction in the atrial contraction that occurs after sympathetic stimulation. Because neuropeptide Y is released on sympathetic activation in many species, including man, 7 -10 -24 -28 it is likely that neuropeptide Y modulates the autonomic control of various aspects of cardiac function under a variety of physiological conditions. The development of specific neuropeptide Y antagonists would greatly enhance our ability to investigate the role of neuropeptide Y in cardiac sympathetic-parasympathetic interactions and to ascertain whether neuropeptide Y released from sympathetic neurons is the sole mediator of the persistent inhibition of cardiac vagal effects that occurs after the cessation of sympathetic stimulation.
